<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111770</url>
  </required_header>
  <id_info>
    <org_study_id>ECRI-013</org_study_id>
    <nct_id>NCT04111770</nct_id>
  </id_info>
  <brief_title>The OPTIMAL Randomized Controlled Trial</brief_title>
  <acronym>OPTIMAL</acronym>
  <official_title>OPtimizaTIon of Left MAin PCI With IntravascuLar Ultrasound. The OPTIMAL Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECRI bv</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philips Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ECRI bv</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OPTIMAL study is a randomized, controlled, multicentre, international study. A total of&#xD;
      800 patients will be randomized in a 1:1 fashion to Intravascular Ultrasound (IVUS)-guided&#xD;
      PCI versus qualitative angio(QCA)-guided Percutaneous Coronary Intervention (PCI). Patients&#xD;
      will be consented prior to the PCI procedure and then followed up to 2 years after the index&#xD;
      procedure.&#xD;
&#xD;
      Patients will be followed-up at 1 month (telephone contact), 12 months (outpatient clinic&#xD;
      visit or telephone call) and 24 months (outpatient clinic visit or telephone call) after the&#xD;
      index procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2020</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-oriented Composite Endpoint (POCE)</measure>
    <time_frame>2 years follow up</time_frame>
    <description>Patient-oriented Composite Endpoint (PoCE): composite of all-cause death, any stroke, any myocardial infarction (MI)*, any clinically indicated revascularization at 2 years follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device-oriented Composite Endpoint (DoCE)</measure>
    <time_frame>1 and 2 years follow up</time_frame>
    <description>Device-oriented Composite Endpoint (DoCE) defined as the composite of: Cardiovascular death, target vessel MI, clinically indicated repeat revascularization of the target lesion at 1 and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vessel-oriented Composite Endpoint (VoCE)</measure>
    <time_frame>1 and 2 years follow up</time_frame>
    <description>Vessel-oriented Composite Endpoint (VoCE) defined as the composite of: left main related cardiac death, target vessel MI, clinically indicated -repeat revascularization of the left main vessels at 1 and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented Composite Endpoint (POCE)</measure>
    <time_frame>1 year follow up</time_frame>
    <description>Patient-oriented Composite Endpoint (PoCE): composite of all-cause death, any stroke, any myocardial infarction (MI)*, any clinically indicated revascularization at 2 years follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All individual components of PoCE at all time points.</measure>
    <time_frame>1 and 2 years follow up</time_frame>
    <description>All individual components of PoCE at all time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All individual components of DoCE at all time points.</measure>
    <time_frame>1 and 2 years follow up</time_frame>
    <description>All individual components of DoCE at all time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite and probable stent thrombosis</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Definite and probable stent thrombosis according to ARC definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>2 years</time_frame>
    <description>Investigator reported hospitalization for heart failure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Left Main Coronary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>IVUS guided PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QCA guided PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QCA will be used to determine lesion characteristics</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IVUS guided Percutaneous Coronary Intervention</intervention_name>
    <description>Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.</description>
    <arm_group_label>IVUS guided PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>QCA guided Percutaneous Coronary Intervention</intervention_name>
    <description>QCA will be used to determine lesion characteristics</description>
    <arm_group_label>QCA guided PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must be ≥ 18 years of age;&#xD;
&#xD;
          2. De novo lesion of the LM (ostial, shaft or distal) where PCI is considered appropriate&#xD;
             and feasible by the Heart Team*.&#xD;
&#xD;
          3. Stable or unstable angina, non-ST segment myocardial infarction, documented silent&#xD;
             ischemia or a positive functional study (e.g. by pressure or angiography derived&#xD;
             indices).&#xD;
&#xD;
          4. Any left-main Medina classification 100, 110, 101, 011, 010, 111, 001 (left-main&#xD;
             equivalent) can be included.&#xD;
&#xD;
          5. A patient with a previous coronary artery bypass graft (CABG) with no patent bypass on&#xD;
             the LCA may be included.&#xD;
&#xD;
          6. Able to understand and provide informed consent and comply with all study procedures,&#xD;
             including follow-up for at least 2 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed&#xD;
             within 7 days prior to the index procedure in women of child-bearing potential).&#xD;
&#xD;
          2. Ongoing MI or recent MI with cardiac biomarker levels still elevated.&#xD;
&#xD;
          3. Previous history of CABG with patent Left Internal Mammary Artery (LIMA) to LAD and/or&#xD;
             patent graft to the left circumflex coronary.&#xD;
&#xD;
          4. Prior PCI of the left-main or the ostium of the LAD or the ostium of the LCX at any&#xD;
             time prior to enrolment.&#xD;
&#xD;
          5. Prior PCI in LCA (e.g. mid LAD) within the previous 30 days.&#xD;
&#xD;
          6. Known intolerance to any antiplatelet agent that would prevent a 12 month dual&#xD;
             antiplatelet therapy (DAPT) duration&#xD;
&#xD;
          7. Patients requiring additional surgery (cardiac or non-cardiac) within 3 months post&#xD;
             randomization.&#xD;
&#xD;
          8. Non-cardiac co-morbidities with a life expectancy less than 2 years.&#xD;
&#xD;
          9. Currently participating in another trial and not yet at its primary endpoint. The&#xD;
             patient is not allowed to participate in another investigational device or drug study&#xD;
             for at least 12 months after enrolment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Banning, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luca Testa, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinco San Donato</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ernest Spitzer, MD</last_name>
    <email>E.Spitzer@ECRI-Trials.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giulio Guagliumi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Interventistica Cardiologica Strutturale</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carlo di Mario</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Niguarda</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jacopo Oreglia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinco San Donato</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luca Testa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sant'Ambrogio Clinical Institute</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alfonso Ielasi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bernard Reimers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOUI Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de A Coruña</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pablo Pinon Esteban</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gomez-Lara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bruno Garcia del Blanco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Manuel Pan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Cabueñes</name>
      <address>
        <city>Gijon</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Iñigo Lozano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universiatrio V. Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose Maria de la Torre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Alvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andres Iñiguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jose Ruiz Arroyo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Simon Walsh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter O'Kane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Sussex Country Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>James Cockburn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Royal infirmary</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tom Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrew Sharp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Clydebank</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Margaret McEntegart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>John Greenwood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andreas Baumbach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St' George's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>James Spratt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Azfar Zaman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gianluigi de Maria</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Javaid Iqbal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IVUS</keyword>
  <keyword>PCI</keyword>
  <keyword>Left Main</keyword>
  <keyword>QCA</keyword>
  <keyword>Treatment Strategy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

